Business Context and Reporting Period
Healthcare Triangle, Inc. filed this Form 8-K on December 14, 2021, reporting events occurring on December 10, 2021. The company completed its acquisition of Devcool, Inc., a provider of consulting, implementation, support, managed and information technology services, including electronic health records services for business and healthcare clients.
Transaction and Key Financial Terms
- Healthcare Triangle acquired all 5,000,000 outstanding shares of Devcool Class B Common Stock.
- Total consideration may be up to $7.7 million, consisting of:
- $4.5 million in cash paid at closing.
- $700,000 in Healthcare Triangle common stock, including 209,295 unvested shares issued to the seller and 83,718 unvested retention shares issued to key personnel.
- Up to $2.5 million in post-closing earnout consideration, split between cash and stock and dependent on achievement of Year 1 and Year 2 targets.
- The company issued an additional 125,577 shares to the seller in connection with the release of claims by Devcool’s CEO.
- On December 10, 2021, the company issued a total of 418,590 shares: 334,872 shares to the seller and 83,718 shares to retention personnel. The issuances relied on the Securities Act Section 4(a)(2) exemption.
- The company issued a secured, non-interest-bearing promissory note with principal of $2,208,840.96, maturing March 31, 2022. The note reflects the difference between Devcool’s closing-date accounts receivable and accounts payable and may be reduced for receivables not collected by maturity.
- The note is secured by substantially all of Healthcare Triangle’s assets, including accounts receivable, contract rights, intellectual property, equipment, inventory, deposit accounts, investment property, proceeds and the acquired Devcool shares.
- Healthcare Triangle entered into a consulting agreement with Devcool’s CEO through March 31, 2024, with minimum annual compensation of $120,000 plus customary benefits.
Material Changes Versus the Prior Comparable Period
The filing does not provide comparative financial statements or prior-period operating metrics. The material change reported is the completed acquisition of Devcool, together with the related cash payment, equity issuance, contingent earnout obligations, promissory note and security interest.
Guidance, Outlook, Risks and Unusual Items
- No financial guidance or quantified operating outlook is provided.
- Future earnout payments of up to $2.5 million depend on Devcool meeting specified annual targets and may be paid in cash, stock or both.
- The retention shares vest monthly over 24 months, subject to continued service.
- The seller’s note creates a near-term maturity obligation and is secured by substantially all of the company’s assets.
- The acquisition consideration and related obligations could result in additional dilution, cash requirements and contingent liabilities.
- The filing does not provide Devcool’s historical revenue, profitability, cash flow, debt, liquidity or margin information.
Important Facts for Investors to Verify
- Review the full Share Purchase Agreement, promissory note and Security Agreement filed as Exhibits 10.1, 10.2 and 10.3.
- Verify the final purchase accounting, including the fair value of issued shares, contingent earnouts and acquired assets and liabilities.
- Monitor Devcool’s performance against the Year 1 and Year 2 earnout targets.
- Assess collection of the closing-date receivables before the March 31, 2022 note maturity.
- Evaluate the effect of the issued and potentially issuable shares on ownership dilution.
- Determine whether the filing text does not provide a clear value for Devcool’s standalone revenue, profit, cash flow, margins, debt or liquidity.